Discover how tirzepatide, a first‑in‑class dual GIP/GLP‑1 “twincretin,” delivers up to ~20% body weight reduction, improves cardiometabolic risk factors, and bridges the gap between obesity pharmacotherapy and metabolic surgery.
Learn how tirzepatide, a dual GIP and GLP‑1 receptor agonist, delivers powerful blood sugar control and significant weight loss, redefining treatment standards for type 2 diabetes and obesity.
Learn how tirzepatide, a dual GIP/GLP‑1 receptor agonist, differs from traditional GLP‑1 drugs like semaglutide. Discover its mechanism, once‑weekly dosing, and impact on blood sugar, weight loss, and cardiometabolic risk in type 2 diabetes and obesity.